Live Quote · OTCINTIHealthcare· Biotechnology

Inhibitor Therapeutics, Inc.

$0.08 1.25%($-0.00)
TickerSpark Score
52/100
Mixed
60
Valuation
40
Profitability
30
Growth
68
Health
60
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTI research report →

52-Week Range49% of range
Low
$0.04
Current
$0.08
High
$0.12
Company Overviewwww.inhibitortx.com

About the company

Inhibitor Therapeutics, Inc. , established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions.

CEO
Francis E. O'Donnell Jr.
IPO
2013
Employees
3
HQ
Tampa, FL, US

Price Chart

+64.79% · this period
$0.12$0.08$0.04Jul 02Dec 31Jul 02
Valuation
Market Cap
$13.63M
P/E
-4.07
P/S
0.00
P/B
-6.89
EV/EBITDA
-3.63
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
525.87%
ROIC
-319.23%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-3,300,337 · 1.16%
EPS
$-0.02 · 1.55%
Op Income
$-3,426,653
FCF YoY
0.05%
Performance & Tape
52W High
$0.12
52W Low
$0.04
50D MA
$0.08
200D MA
$0.07
Beta
-0.78
Avg Volume
10.60K

Get TickerSpark's AI analysis on INTI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 4, 26Jerman Michael Allenother50,000
May 5, 26Vasisht Nirajother50,000
Apr 1, 25Vasisht Nirajother50,000
Apr 1, 25Yanez Michelleother50,000
Apr 1, 25SEARS SAMUEL P JRother50,000
Apr 1, 25OSMAN RONALD Eother50,000
Apr 1, 25Jerman Michael Allenother50,000
Dec 31, 24MCNULTY JAMES Aother0
Dec 31, 24Yanez Michelleother0
Apr 1, 24Yanez Michelleother50,000
Coverage · INTI

Our INTI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on INTI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate INTI report →
Internal Compare

Similar companies

Peers in the same neighborhood.